Evidence map›Paper›PMID 36253952›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy.

Kelly A Johnson, Hideaki Okochi, Mireya Arreguin, Joseph Watabe, David V Glidden, Anindita Chattopadhyay, Elizabeth Imbert, Matthew D Hickey, Monica Gandhi, Matthew Spinelli

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kelly A JohnsonDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-3333-099X
Hideaki OkochiDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Mireya ArreguinDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Joseph WatabeDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA.
Anindita ChattopadhyayDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Elizabeth ImbertDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Matthew D HickeyDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Matthew SpinelliDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
Urine tenofovir point-of-care test to identify patients in need of ART adherence supportR01AI152119 · NIAID · STELLENBOSCH UNIVERSITY · PI GANDHI, MONICA, ORRELL, CATHERINE · 2020 to 2024
$1.7M
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)K23MH122286 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPINELLI, MATTHEW A. · 2020 to 2024
$1.0M
NIAID NIH HHS R01 AI143340NIAID NIH HHS R01 AI152119NIMH NIH HHS K23 MH122286
6 · The paper itself

Abstract

We found that urine tenofovir (TFV) levels >1500 ng/mL strongly predict virologic suppression among people with human immunodeficiency virus taking tenofovir alafenamide (odds ratio, 5.66; 95% confidence interval, 1.59-20.14; P = .007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate will support adherence monitoring for patients on all TFV-based antiretrovirals.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAdenineAlanineHumansTenofovirAdenineAlanineAnti-HIV AgentsTenofoviradherencepoint-of-care monitoringtenofovir alafenamideviral suppression

Identifiers

PMID36253952
PMCPMC10226738
OpenAlexW4306673011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.